Ook interessant
ADMIRAL trial (2019)
Publication
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Find out moreXOSPATA patient brochure
Information about treatment with gilteritinib. It does not replace the package leaflet.
Find out more
Gilteritinib post TKI (2022)
Publication
Clinical outcomes in patients with relapsed/refractory FLT3- mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
MAT-BE-XOS-2023-00022 - November 2023